H. Lundbeck A/S (OTCMKTS:HLUYY) Sets New 52-Week Low at $27.00

H. Lundbeck A/S (OTCMKTS:HLUYY) reached a new 52-week low on Wednesday . The stock traded as low as $27.00 and last traded at $27.00, with a volume of 1493 shares trading hands. The stock had previously closed at $27.79.

HLUYY has been the topic of several analyst reports. Zacks Investment Research upgraded H. Lundbeck A/S from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a report on Monday, August 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on H. Lundbeck A/S in a report on Friday, July 23rd. They set a “sell” rating and a $30.67 target price on the stock. Credit Suisse Group reiterated an “underperform” rating on shares of H. Lundbeck A/S in a report on Friday, August 20th. Finally, Barclays reiterated an “overweight” rating on shares of H. Lundbeck A/S in a report on Thursday, September 2nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, H. Lundbeck A/S currently has an average rating of “Hold” and an average price target of $31.34.

The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.66 and a current ratio of 0.97. The firm has a fifty day simple moving average of $30.01 and a 200-day simple moving average of $32.11. The company has a market capitalization of $5.38 billion, a PE ratio of 16.48 and a beta of 0.70.

H. Lundbeck A/S Company Profile (OTCMKTS:HLUYY)

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer’s, depression, Parkinson’s, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington’s.

Read More: When can a hold rating present a buying opportunity?

Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.